ScholarIQanswers from OpenAlex & ORCID
Stewart Anderson
ResearcherPublications, citations & collaboration network
Stewart Anderson is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Stewart Anderson have?
ScholarIQindexed works
Stewart Anderson has 268 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Stewart Anderson have?
ScholarIQcitation count
Stewart Anderson has 35,051 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Stewart Anderson?
ScholarIQh-index
Stewart Anderson has an h-index of 73 in OpenAlex.
What is the i10-index of Stewart Anderson?
ScholarIQi10-index
Stewart Anderson has an i10-index of 148 in OpenAlex.
What is the ORCID of Stewart Anderson?
ScholarIQorcid
The ORCID for Stewart Anderson is on the source record.
What is the OpenAlex record for Stewart Anderson?
ScholarIQopenalex
The OpenAlex for Stewart Anderson is on the source record.
What are the most-cited papers on Stewart Anderson?
ScholarIQmost cited works
Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer
Bernard Fisher, Stewart Anderson, John Bryant, Richard G. Margolese, Melvin Deutsch, Edwin R. Fisher, Jong‐Hyeon Jeong, Norman Wolmark
Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
David N. Krag, Stewart Anderson, Thomas B. Julian, Ann Brown, Seth P. Harlow, Joseph P. Costantino, Takamaru Ashikaga, Donald L. Weaver, Eleftherios P. Mamounas, Lynne M Jalovec, Thomas G. Frazier, R. Dirk Noyes, André Robidoux, Hugh MC Scarth, Norman Wolmark
Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial
David N. Krag, Stewart Anderson, Thomas B. Julian, Ann Brown, Seth P. Harlow, Takamaru Ashikaga, Donald L. Weaver, Bárbara Miller, Lynne M Jalovec, Thomas G. Frazier, R. Dirk Noyes, André Robidoux, Hugh MC Scarth, Denise Mammolito, David R. McCready, Eleftherios P. Mamounas, Joseph P. Costantino, Norman Wolmark
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
Rosie Bradley, Jeremy Braybrooke, Richard J. Gray, Robert K. Hills, Zulian Liu, Richárd Pető, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn Taylor, Stewart Anderson, Richard D. Gelber, Luca Gianni, William Jacot, Heikki Joensuu, Alvaro Moreno‐Aspitia, Martine Piccart, Michael F. Press, Edward H. Romond, Dennis J. Slamon, Vera J. Suman, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Frances Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Yaochen Wang, John Crown, Evandro de Azambuja, Suzette Delaloge, Helena Fung, Charles E. Geyer, M. Spielmann, Pinuccia Valagussa, Kathy S. Albain, Stewart Anderson, R. Arriagada, John Bartlett, Elizabeth Bergsten-Nordström, Judith M. Bliss, Étienne Brain, Lisa Carey, Robert E. Coleman, Jack Cuzick, Nancy E. Davidson, Lucia Del Mastro, Angelo Di Leo, James J. Dignam, Mitch Dowsett, Bent Ejlertsen, Prue Francis, Michael Gnant, Matthew Bidwell Goetz, Pam Goodwin, Pat Halpin-Murphy, Daniel Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P. Mamounas, Miguel Martín, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Lori J. Pierce, Philip Poortmans, Vinod Raina, Daniel Rea, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Tanja Španić, Joseph A. Sparano, Guenther G. Steger, Gong Tang, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Xiang Wang, Timothy J. Whelan, Nicholas Wilcken, Norman Wolmark, David Cameron, Jonas Bergh, Kathleen I. Pritchard
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials
Jeremy Braybrooke, Rosie Bradley, Richard Gray, Robert K. Hills, Hongchao Pan, Richárd Pető, David Dodwell, Paul McGale, Carolyn Taylor, Tomohiko Aihara, Stewart Anderson, Joanne L. Blum, Fátima Cardoso, Xiaosong Chen, John Crown, Bent Ejlertsen, Thomas W. P. Friedl, Nadia Harbeck, Wolfgang Janni, Maj‐Britt Jensen, E. Mamounas, Kazutaka Narui, Ulrike Nitz, Larry Norton, Joyce O’Shaughnessy, Martine Piccart, Nicholas J. Robert, Zhi‐Ming Shao, Dennis Slamon, Joseph A. Sparano, Toru Watanabe, Greg Yothers, Ke‐Da Yu, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Lucy Davies, Frances Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Lui, Zulian Lui, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Aman U. Buzdar, Vera J. Suman, Kelly K. Hunt, Robert Leonard, Janine Mansi, Catherine Delbaldo, Pascal Piedbois, Emmanuel Quinaux, Christian Fesl, Michael Gnant, Lidija Sölkner, Guenther G. Steger, Hans Petter Eikesdal, Per Eystein Lønning, Valerie Bée, Helena Fung, John R. Mackey, Miguel Martín, Michael F. Press, Evandro de Azambuja, Richard D. Gelber, Meredith M. Regan, Angelo Di Leo, Veerle Van Dooren, J.-M. Nogaret, John M.S. Bartlett, Bingshu E. Chen, Karen A. Gelmon, Paul E. Goss, Mark N. Levine, Wendy R. Parulekar, Kathleen I. Pritchard, Lois E. Shepherd, Donald A. Berry, Constance Cirrincione, Lawrence N. Shulman, Eric P. Winer, Rebecca Gelman, Jay R. Harris, Craig Henderson, Charles L. Shapiro, Peer Christiansen, Marianne Ewertz, Henning T. Mouridsen, Elise Van Leeuwen, Sabine C. Linn, Annelot G.J. van Rossum, Harm van Tinteren